Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT05677334
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 210 participants
- Registry
-
NCT05677334
-
- Other papers using this trial's data
- A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05677334. Randomized; no masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2024-10-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
- Condition
- Type2diabetes
- Intervention (Drug)
- Henagliflozin
- Intervention (Device)
- Continuous Subcutaneous Insulin Infusion
- Lead sponsor
- First Affiliated Hospital of Guangxi Medical University
Record details
- Record id
cardio:ct-nct05677334- Content hash
bcb3d2923eae5aa07ee9f4041651d39d1d818fe3f7553ba76f5f53c86cc449a9